Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Peking Union Medical College Hospital
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05342506CT.gov Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gestational Trophoblastic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sctil (this asset) | Peking Union Medical College Hospital | P2 | CCC · 53 |
| Amifostine | Gynecologic Oncology Group | P3 | B |
| Nivestim | Fred Hutchinson Cancer Center | P2 | B |
| Alemtuzumab | Fred Hutchinson Cancer Center | P2 | B |
| Moxifloxacin | OHSU Knight Cancer Institute | P3 | B |
| Tacrolimus | Case Comprehensive Cancer Center | P2 | B |
| Sargramostim | Cancer Treatment Centers of America | P2 | B |
| Ondansetron | Fred Hutchinson Cancer Center | P2 | B |
| Alpha-Interferon | Cancer Treatment Centers of America | P2 | B |
+17 more in the Gestational Trophoblastic Neoplasm cohort
Other indications for Sctil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cervical Cancer | — | P2 | CCC · 48 |
| Ovarian Cancer | — | P2 | CC · 46 |
| Digestive System Cancer | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sctil in Gestational Trophoblastic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sctil-gestational-trophoblastic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →